Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Retina Associates of Kentucky
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• age 18 or over

• active choroidal neovascularization secondary to ocular histoplasmosis

• Visual acuity between 20/25 and 20/400

Exclusion Criteria:

• pregnancy or intent to become pregnant within the next 12 months

• nursing an infant

• premenopausal women not using contraception

• prior treatment with subfoveal thermal laser

• allergy to sodium fluorescein simultaneous participation in another investigation or trial